# Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

> **NCT04163419** · PHASE2 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 9 (actual)

## Conditions studied

- Schwannomatosis
- Pain

## Interventions

- **DRUG:** Tanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04163419
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-30
- **Primary completion:** 2022-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04163419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04163419, "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04163419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*